BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 16206675)

  • 21. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
    Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
    Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].
    Sawada H; Wake A; Yamasaki Y; Izumi Y
    Rinsho Ketsueki; 2000 Jun; 41(6):500-6. PubMed ID: 10921350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and feasibility of granulocyte colony-stimulating factor (G-CSF) primed bone marrow (BM) using three days of G-CSF priming as stem cell source for pediatric allogeneic BM transplantation.
    Hussein AA; Sharma S; Al-Zaben A; Frangoul H
    Pediatr Transplant; 2014 Sep; 18(6):625-30. PubMed ID: 25041793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone.
    Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF
    Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V; Ferguson KF; Heller G; Kernan NA
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation.
    Lickliter JD; McGlave PB; DeFor TE; Miller JS; Ramsay NK; Verfaillie CM; Burns LJ; Wagner JE; Eastlund T; Dusenbery K; Weisdorf DJ
    Bone Marrow Transplant; 2000 Oct; 26(7):723-8. PubMed ID: 11042652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hematologic recovery in patients who are treated with autologous stem cells transplantation taken from bone marrow after granulocyte-colony-stimulating factor stimulation.
    Gawronski K; Rzepecki P; Oborska S; Wasko-Grabowska A
    Transplant Proc; 2011 Oct; 43(8):3114-5. PubMed ID: 21996240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of granulocyte colony stimulating factor on myeloid-derived suppressor cells in the bone marrow and peripheral blood: a preliminary study].
    Ling YW; Liu QF; Liu C; Wu XL; Chen YK; Fan ZP; Xuan L; Zhang Y; Jiang QL; Zhao J; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1190-2. PubMed ID: 21764692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation.
    Zhao XY; Xu LL; Lu SY; Huang XJ
    Eur J Immunol; 2011 Feb; 41(2):514-26. PubMed ID: 21268020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
    Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
    Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
    Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
    Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved outcomes using G-CSF-mobilized blood and bone marrow grafts as the source of stem cells compared with G-PB after HLA-identical sibling transplantation in patients with acute leukemia.
    Zhao XS; Chen Y; Zhao XY; Liu DH; Xu LP; Wang Y; Han W; Chen YH; Chen H; Zhang XH; Liu KY; Huang XJ
    Clin Transplant; 2013; 27(6):844-51. PubMed ID: 23992032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation.
    Lv M; Zhao XS; Hu Y; Chang YJ; Zhao XY; Kong Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Am J Hematol; 2015 Jan; 90(1):E9-E16. PubMed ID: 25303038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Randomized clinical study for two types of recombinant human granulocyte colony-stimulating factor mobilizing peripheral blood and bone marrow stem cells in patients receiving allogeneic hematopoietic stem cell transplantation].
    Zhang XH; Huang XJ; Liu DH; Liu KY; Han W; Chen H; Wang FR; Chen YH; Wang JZ; Zhao T; Wang Y; Xu LP
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2116-9. PubMed ID: 20058615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.